- Winterhoff, Boris;
- Kommoss, Stefan;
- Heitz, Florian;
- Konecny, Gottfried E;
- Dowdy, Sean C;
- Mullany, Sally A;
- Park-Simon, Tjoung-Won;
- Baumann, Klaus;
- Hilpert, Felix;
- Brucker, Sara;
- du Bois, Andreas;
- Schröder, Willibald;
- Burges, Alexander;
- Shen, Steven;
- Wang, Jinhua;
- Tourani, Roshan;
- Ma, Sisi;
- Pfisterer, Jacobus;
- Aliferis, Constantin F
We report recent progress in the development of a precision test for individualized use of the VEGF-A targeting drug bevacizumab for treating ovarian cancer. We discuss the discovery model stage (i.e., past feasibility modeling and before conversion to the production test). Main results: (a) Informatics modeling plays a critical role in supporting driving clinical and health economic requirements. (b) The novel computational models support the creation of a precision test with sufficient predictivity to reduce healthcare system costs up to $30 billion over 10 years, and make the use of bevacizumab affordable without loss of length or quality of life.